Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2023-04-28 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物2022年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制评价报告' which translates to '2022 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2022, including financial and non-financial internal control defects, audit opinions, and corrective actions. The content is focused on internal control evaluation rather than full financial statements or annual performance. It is a standalone report on internal control evaluation, not a full annual report (10-K) or audit report of financial statements. The document length is 4732 characters, which is sufficient for a detailed report. The nature of the document aligns with an Audit Report / Information (AR) category, as it covers internal control evaluation results and related audit opinions, but is not the full annual report. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-28 Chinese
安旭生物2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the 2022 annual report summary of Hangzhou Anxu Biotechnology Co., Ltd. It contains detailed financial data for the year 2022, including total assets, net profit, revenue, and quarterly breakdowns. It also includes extensive business descriptions, industry analysis, risk factors, shareholder information, and dividend distribution plans. The presence of comprehensive financial statements, management discussion, and analysis of business operations indicates this is a full annual report rather than a brief announcement or a presentation. The document length (12,075 characters) supports it being a substantive report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2023-04-28 Chinese
杭州安旭生物科技股份有限公司控股子公司管理制度
Governance Information Classification · 95% confidence The document is titled '控股子公司管理制度' which translates to 'Management System for Controlling Subsidiaries' issued by 杭州安旭生物科技股份有限公司 (Hangzhou Anxu Biotechnology Co., Ltd.) in April 2023. The content outlines detailed internal management rules and procedures for controlling subsidiaries, covering governance, personnel, financial management, investment, information management, audit supervision, and performance evaluation. It is a governance and internal control policy document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results, nor is it a notice or announcement of a report. The document fits best under Governance Information (CGR) as it details the company's internal rules and governance practices related to subsidiary management.
2023-04-28 Chinese
安旭生物2023年第一季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled '2023 年第一季度报告' which translates to '2023 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2023. The report explicitly states it is unaudited and covers the period January to March 2023. It includes comprehensive financial metrics, shareholder information, and management assurances about the accuracy of the report. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. The document length is over 12,000 characters, indicating it is the full report, not just an announcement or summary. Therefore, the correct classification is IR with high confidence. Q1 2023
2023-04-28 Chinese
安旭生物第二届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Hangzhou Anxu Biotechnology Co., Ltd. It details the approval of various reports and proposals related to the company's 2022 annual report, financial statements, profit distribution, internal control evaluation, asset impairment provisions, and the 2023 first quarter report. The document references the company's 2022 annual report and 2023 first quarter report but does not contain the full reports themselves. It also states that these reports are disclosed on the Shanghai Stock Exchange website. The document is relatively short (3170 characters) and serves as a formal announcement of the Supervisory Board's meeting resolutions and approvals, not the full annual or quarterly reports. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement of meeting resolutions and approvals related to various reports, rather than the reports themselves.
2023-04-28 Chinese
民生证券股份有限公司关于杭州安旭生物科技股份有限公司2022年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report on the 2022 annual usage and management of funds raised by Hangzhou Anxu Biotechnology Co., Ltd., including specifics on the amount raised, usage, storage, and regulatory compliance. It includes audit opinions from an accounting firm and verification by the sponsoring institution. The content focuses on the management and use of raised capital, consistent with a specialized audit or verification report on fundraising activities rather than a full annual report or earnings release. The document is lengthy (15,000 characters) and contains substantive financial data and analysis related to fundraising and capital usage. This matches the description of an Audit Report / Information (AR) filing, which covers standalone audit reports and results of internal or regulatory checks excluding full annual reports. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.